News

November 7, 2018

Rhythm Pharmaceuticals to Present at Stifel 2018 Healthcare Conference

October 15, 2018

Rhythm Pharmaceuticals Appoints Murray W. Stewart, M.D., as Chief Medical Officer

September 28, 2018

Rhythm Pharmaceuticals Announces Launch of TEMPO Registry for Rare Genetic Disorders of Obesity

September 28, 2018

Rhythm Pharmaceuticals Announces Presentation of Updated Clinical Data from Phase 2 Basket Studies Evaluating Setmelanotide in Bardet-Biedl Syndrome and Alström Syndrome at 57th Annual ESPE Meeting

September 25, 2018

Rhythm Pharmaceuticals to Present at Ladenburg Thalmann 2018 Healthcare Conference

September 7, 2018

Rhythm Pharmaceuticals to Present at Morgan Stanley 16th Annual Global Healthcare Conference

August 8, 2018

Rhythm Pharmaceuticals Reports Second Quarter 2018 Financial Results

July 23, 2018

Rhythm Pharmaceuticals Receives European Medicines Agency PRIME Designation for Setmelanotide in Rare Genetic Disorders of Obesity

June 25, 2018

Rhythm Pharmaceuticals, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

June 20, 2018

Rhythm Pharmaceuticals, Inc. Announces Pricing of Public Offering